...
首页> 外文期刊>Therapeutics and Clinical Risk Management >Artificial Neural Network Model for Liver Cirrhosis Diagnosis in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma
【24h】

Artificial Neural Network Model for Liver Cirrhosis Diagnosis in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma

机译:乙型肝炎病毒相关肝细胞癌患者肝硬化诊断人工神经网络模型

获取原文

摘要

Background: Testing for the presence of liver cirrhosis (LC) is one of the most critical diagnostic and prognostic assessments for patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). More non-invasive tools are needed to diagnose LC but the predictive abilities of current models are still inconclusive. This study aimed to develop and validate a novel and non-invasive artificial neural network (ANN) model for diagnosing LC in patients with HBV-related HCC using routine laboratory serological indicators. Methods: A total of 1152 HBV-related HCC patients who underwent hepatectomy were included and randomly divided into the training set (n = 864, 75%) and validation set (n = 288, 25%). The ANN model was constructed from the training set using multivariate Logistic regression analysis and then verified in the validation set. Results: The morbidity of LC in the training and validation sets was 41.2% and 46.8%, respectively. Multivariate analysis showed that age, platelet count, prothrombin time and total bilirubin were independent risk factors for LC ( P 0.05). The area under the ROC curve (AUC) analyses revealed that the ANN model had higher predictive accuracy than the Logistic model (ANN: 0.757 vs Logistic: 0.721; P 0.001), and other scoring systems (ANN: 0.757 vs CP: 0.532, MELD: 0.594, ALBI: 0.575, APRI: 0.621, FIB-4: 0.644, AAR: 0.491, and GPR: 0.604; P 0.05 for all) in diagnosing LC. Similar results were obtained in the validation set. Conclusion: The ANN model has better diagnostic capabilities than other commonly used models and scoring systems in assessing LC risk in patients with HBV-related HCC.
机译:背景:肝硬化(LC)的存在测试是乙型肝炎病毒(HBV)相关肝细胞癌(HCC)患者最关键的诊断和预后评估之一。需要更多的非侵入性工具来诊断LC,但目前模型的预测能力仍然不确定。该研究旨在使用常规实验室血清学指示剂开发和验证用于诊断HBV相关的HCC患者诊断LC的新型和非侵入式人工神经网络(ANN)模型。方法:共有1152例HBV相关的HCC患者接受肝切除术,并随机分为训练组(n = 864,75%)和验证组(n = 288,25%)。 ANN模型由使用多变量逻辑回归分析的训练集构成,然后在验证集中验证。结果:培训和验证套装中LC的发病率分别为41.2%和46.8%。多变量分析表明,年龄,血小板计数,凝血酶原和总胆红素是LC的独立危险因素(P <0.05)。 ROC曲线(AUC)分析下的区域揭示了ANN模型的预测精度高于物流模型(ANN:0.757 VS Logistic:0.721; P <0.001)和其他评分系统(ANN:0.757 VS CP:0.532, MELD:0.594,ALBI:0.575,APRI:0.621,FIB-4:0.644,AAR:0.491,GPR:0.604;所有的GPR:0.604; P <0.05,适用于全部)。在验证集中获得了类似的结果。结论:ANN模型具有比其他常用模型和评分系统评估HBV相关的HCC患者LC风险的诊断能力更好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号